Multicentre study with a new biphasic oral contraceptive containing ethinylestradiol and desogestrel. Report on efficacy, cycle control and adverse experiences with special emphasis on blood pressure and weight.
In a multicentre study 882 women were treated during a total of 12850 cycles with a new biphasic oral contraceptive: CTR 24. The study period was 18 cycles. The biphasic preparation CTR 24 contains 25 micrograms desogestrel (CAS 54024-22-5) plus 40 micrograms ethinylestradiol (CAS 57-63-6) daily for the first 7 days followed by the combination of 125 micrograms desogestrel and 30 micrograms ethinylestradiol daily for the subsequent 15 days. One pregnancy occurred. The woman had forgotten one tablet on Day 6 of Cycle 12. The Pearl Index was 0.1 (0.0-0.5) for patient failure. The combination had a good cycle control and only few side effects were reported.
Dieben
T O
TO
Organon International B.V., Oss, The Netherlands.
van Beek
A
A
Coelingh Bennink
H J
HJ
D001794:Blood Pressure / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000494:pharmacology*; D017135:Desogestrel; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008597:Menstrual Cycle / Q000187:drug effects*; D009652:Norpregnenes / Q000009:adverse effects / Q000494:pharmacology*; D011247:Pregnancy
D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D009652:Norpregnenes; D004997:Ethinyl Estradiol; C034653:Oviol; D017135:Desogestrel